文献速递肝病

重新评估传统止血试验对肝硬化围手术期出血的预测价值:肝硬化止血再平衡时代

Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
PubMed 文献 · Hepatology · 2024-01-12

该文讨论肝硬化止血再平衡新范式下,传统止血试验(凝血酶原时间等)无法预测围手术期出血,国际指南警告不应据此输注血浆、凝血因子或血小板,但该建议未被广泛遵守。作者建议开展大型前瞻性协作研究,将患者随机分为基于实验室检测的围手术期预防组、常规治疗组和不接受预防的第三组。在结果可用前,医生应避免使用任意切点的实验室检测决定围手术期预防,而应依据患者临床病史和具体操作出血风险决策。

要点

  • 凝血酶原时间及其同类试验无法预测肝硬化患者围手术期出血。
  • 国际指南警告不应根据传统止血试验异常在手术/侵入性操作前输注新鲜冰冻血浆、凝血因子浓缩物或血小板。
  • 在大型前瞻性协作研究结果可用前,医生应避免使用任意切点的实验室检测决定围手术期预防。

核心结论

  • 凝血酶原时间及其同类试验无法预测肝硬化患者出血,但不能排除某些检测对严重失代偿患者可能有用。
  • 在大型前瞻性协作研究结果可用前,医生应避免使用任意切点的实验室检测决定围手术期预防,决策应依据个体患者临床病史和具体操作出血风险。

研究设计与样本

  • 本文为综述,讨论肝硬化止血再平衡范式下传统止血试验对围手术期出血的预测价值。
  • 作者提出需开展大型前瞻性协作研究,将入组患者随机分为基于实验室检测(如粘弹性检测、血栓调节蛋白修饰的凝血酶生成)的围手术期预防组或常规治疗组,并需包含不接受预防的第三组患者。

主要发现

  • 凝血酶原时间及其同类试验无法预测肝硬化患者出血。
  • 国际指南警告不要对传统止血试验异常的患者在手术/侵入性操作前输注新鲜冰冻血浆、凝血因子浓缩物或血小板,但这些建议在很大程度上未被遵守。
  • 使用凝血酶原时间或粘弹性检测及任意切点决定围手术期预防的做法仍很常见,可能由医疗法律问题驱动。

临床怎么用

  • 国际指南警告不要对传统止血试验异常的患者在手术/侵入性操作前输注新鲜冰冻血浆、凝血因子浓缩物或血小板。
  • 作者认为,在大型前瞻性协作研究结果可用前,医生应避免使用任意切点的实验室检测决定围手术期预防。
  • 作者认为,决策应依据个体患者临床病史和具体操作的出血风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New global laboratory procedures mimicking the in vivo hemostasis process led to the changing paradigm of cirrhosis from the prototype of hemorrhagic diseases to a condition in which hemostasis is normal but fragile, thus justifying the hemorrhagic/thrombotic tendencies that affect these patients. The new paradigm was instrumental to change the management of cirrhosis. For example, international guidelines warn against the entrenched practice of testing patients with conventional hemostasis tests and infusing those with abnormalities with fresh-frozen plasma, coagulation factor concentrates, or platelets, prior to surgery/invasive procedures. These recommendations are, however, largely disattended. The practice of testing patients with the prothrombin time or viscoelastometry and using arbitrary cutoffs to make decisions on perioperative prophylaxis is still common and probably driven by medicolegal issues. There is no doubt that prothrombin time and congeners tests are unable to predict bleeding in cirrhosis. However, it cannot be excluded that some tests may be useful in patients who are severely decompensated. Large prospective collaborative studies are warranted. Enrolled patients should be randomized to receive perioperative prophylaxis based on laboratory testing (eg, viscoelastometry, thrombomodulin-modified thrombin generation) or to usual care. However, for these trials to be useful, a third group of patients who do not receive prophylaxis should be included. In conclusion, until results from these studies are available, physicians attending cirrhosis should refrain from using laboratory tests with arbitrary cutoffs to make decision on perioperative prophylaxis. Decision should be made by considering the clinical history of individual patients and the risk of hemorrhage of specific procedures.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tripodi A, Primignani M, D'Ambrosio R, et al. Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis. Hepatology. 2024. PMID: 38214562. doi:10.1097/HEP.0000000000000756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。